Markers for hypercoagulation can be used to explain why some patients may have had
thromboembolic disease (TED). This information may then be applied to estimate risk for …

BACKGROUND: Routine thrombophilia testing is controversial because of the low yield of
positive tests, costs involved, and debate about the clinical usefulness of the data obtained …

Venous thromboembolic disease (VTD) affects 1 in 1,000 persons each year in the United
States, causing more than 50,000 deaths.(1, 2) Common clinical manifestations of the …

Venous thromboembolism affects 0.1% of the general population in the United States every
year, resulting in more than 50,000 deaths annually. Common predisposing conditions …

Venous thrombosis (VT) is a disease that occurs in approximately 1–2 per 1000 persons per
year [1]. Despite adequate treatment, up to one quarter of patients with VT will experience a …

Selected blood tests may be useful in the diagnosis of venous thromboembolism (VTE), or in
the identification of a congenital or acquired defect associated with the development of VTE …

Objective.—To provide recommendations for hypercoagulation testing for patients with
venous, arterial, or neurovascular thrombosis, as reflected in the medical literature and the …

Mounting interest in hypercoagulability, increased availability of hypercoagulable state test
'panels' and enhanced ability to identify abnormalities in tested patients have prompted …

Vessel wall injury, stasis, and blood hypercoagulable state are major predisposing factors of
thrombosis. Although, a procoagulable factor is found in half of patients with venous …

Early in the course of caring for a patient who has venous thromboembolism (VTE), the
clinician may consider whether to test for a hypercoagulable disorder that could lead to …